Click here to download our corporate presentation
BIOPHYTIS is a biotechnology company created in 2006, specialising in diseases associated with aging, particularly those affecting muscular and visual functions.
Aging science
By understanding the relationship between natural active substances and degeneration processes BIOPHYTIS is able to identify families of substances capable of acting directly on the mechanism of the disease.
BIOPHYTIS has a portfolio of first-in-class drug candidates, at various stages of development, for treating certain indications of sarcopenia and AMD, for which there is currently no treatment.
13 September 2018

Biophytis obtains a €10 million loan with Kreos Capital. Read the Press Release

04 September 2018

Biophytis Provides Enrollment Update in Its Phase 2b SARA-OBS and SARA-INT Studies of Sarconeos in Sarcopenia. Read the Press Release